Simple diffusion delivery via brain interstitial route for the treatment of cerebral ischemia by HongBin Han et al.
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2011. This article is published with open access at Springerlink.com life.scichina.com   www.springer.com/scp 
                  
*Corresponding author (email: hanhongbin@bjmu.edu.cn; xiazuoli@163.com) 
• RESEARCH  PAPERS • March 2011  Vol.54  No.3: 235–239 
 doi: 10.1007/s11427-011-4141-6 
Simple diffusion delivery via brain interstitial route for the 
treatment of cerebral ischemia  
HAN HongBin1*, XIA ZuoLi2*, CHEN He1, HOU Chao1 & LI WeiBo3 
1Department of Radiology, Peking University Third Hospital, Beijing 100191, China; 
2Department of Neurology, Affiliated Hospital, Taishan Medical College, Tai’an 271000, China; 
3Department of Medical Radiation Physics and Diagnostics, Helmholtz Zentrum München, German Research Center for 
Environmental Health (GmbH), Neuherberg 85764, Germany 
Received December 13, 2010; accepted December 20, 2010; published online February 19, 2011 
 
Delivering pharmacologic agents directly into the brain has been proposed as a means of bypassing the blood brain barrier. 
However, despite 16 years of research on a number of central nervous system disorders, an effective treatment using this strat-
egy has only been observed in the brain tumor glioblastoma multiforme. Within this study we propose a novel system for de-
livering drugs into the brain named the simple diffusion (SDD) system. To validate this technique, rats were subjected to a sin-
gle intracranial (at the caudate nucleus), or intraperitoneal injection, of the compound citicoline, followed two hours later by a 
permanent middle cerebral artery occlusion (pMCAO). Results showed that 12 h after pMCAO, with 0.0025 g kg−1 citicoline, 
an infarct volume 1/6 the size of the intraperitoneal group was achieved with a dose 1/800 of that required for the intraperito-
neal group. These results suggest that given the appropriate injection point, through SDD a pharmacologically effective con-
centration of citicoline can be administered.  
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A major obstacle in the development of drugs for use in the 
central nervous system is the ability to generate compounds 
capable of penetrating the blood brain barrier (BBB) [1]. 
One strategy, developed by Oldfield et al. [2], to overcome 
this problem is to bypass the BBB and infuse drugs directly 
into the CNS parenchyma through a process known as con-
vection-enhanced delivery. With this technique a constant 
pressure gradient is maintained during interstitial infusion 
via one or several catheters and there is significantly en-
hanced distribution of a range of molecule sizes and an in-
crease in the locoregional concentration of the infused 
compounds. Despite 16 years of basic research and multiple 
clinical trials using this technique being carried out on 
various CNS diseases [3], effective treatment has only been 
obtained in the brain tumor glioblastoma multiforme [4]. 
In this report, we outline the findings of a novel simple 
diffusion delivery (SDD) system used for the treatment of 
cerebral ischemia. This system is based on previous studies 
examining brain interstitial tracer imaging using MRI [5] 
wherein, we demonstrated that within two hours, using the 
caudate nucleus as the original injection point, small 
molecules like Gd-DTPA are able to diffuse via the brain 
extracellular space to most of the architecture supplied by 
the middle cerebral artery. The compound Gd-DTPA is a 
common MRI contrast agent, which is also an effective 
tracer for monitoring the dynamic distribution of small 
molecules in the interstitial space [6]. Based on the above 
findings, we sought to test the hypothesis that intracerebral 
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administration of the compound citicoline prior to 
ischemic injury would provide a more efficient neuropro-
tective effect than other routes of administration. In the 
current study, citicoline was chosen to test our hypothesis 
because it has a similar polarity and molecular weight to 
Gd-DTPA [7,8].  
1  Materials and methods 
1.1  Animals 
The study was conducted in accordance with national 
guidelines for the care and use of animals. All animal pro-
tocols were approved by the Peking University Health Sci-
ence Center Ethics Committee (Approval No. LA2009-008). 
The animals used in the study were age-matched, mature 
male Sprague Dawley rats weighing approximately 250– 
300 g. 
1.2  Experimental groups 
Citicoline (CDP-choline, cytidine 5′-diphosphocholine) was 
administered by intracranial microinjection into the caudate nu- 
cleus using the following stereotactic coordinates: bregma +1 
mm, lateral 3 mm, vertical 4.5 mm (Lab Standard Stereo-
taxic-Single, Stoelting Co., Illinois, USA). The study of the 
real-time detection of the infarction process by MRI and 
determination of infarct volume by TTC staining was com-
posed of seven groups. For each group the animals (n= 
8/group) received an intracranial (IC) microinjection of (i)  
5 μL saline (control group), (ii) 0.00125 g kg−1 citicoline 
(IC group 1), (iii) 0.0025 g kg−1 citicoline (IC group 2), (iv) 
0.00375 g kg−1 citicoline (IC group 3), (v) 0.005 g kg−1 citi-
coline (IC group 4), (vi) 0.0125 g kg−1 citicoline (IC group 
5). Animals in the final group received an intraperitoneal 
(IP) injection of 2 g kg−1 citicoline (IP group). Two hours 
after receiving an injection of citicoline (or saline), the ani-
mals were then subjected to a permanent middle cerebral 
artery occlusion (pMCAO). The choice to administer citi-
coline two hours prior to pMCAO was based on our previ-
ous study on the diffusion pattern of Gd-DTPA in the brain 
extracellular space [5]. 
1.3  Permanent middle cerebral artery occlusion 
(pMCAO) in rats 
The rats were anesthetized with a compound anesthetic agent 
(sodium pentobarbital, ethanol, chloral hydrate, magnesium 
sulfate, propylene glycol) delivered intraperitoneally. The 
animals’ core temperatures were monitored with a rectal 
thermometer and maintained at approximately (38±0.5)°C 
using a heat pad. Permanent focal cerebral ischemia was 
induced using a technique modified from work presented by 
Longa et al. [9] without the process of vascular recanaliza-
tion for perfusion. After the surgery, all animals were re-
turned to their cages and allowed free access to water and 
food.  
1.4  MRI for pMCAO rats 
Neuroimaging was performed using a 3.0T clinical MR 
system (Magnetom Trio, Siemens Medical Solutions, Er-
langen, Germany). A wrist coil was used for axial T1W, 
T2W and DW images. Parameters for the imaging sequence 
were as follows: (i) 3D MP-RAGE T1WI (echo time (TE)= 
3.7 ms; repetition time (TR)=1500 ms; flip angle α=9°; in-
version time (TI)=900 ms; field of view (FOV)=267 mm; 
voxel=0.5 mm×0.5 mm×0.5 mm; resolution=512×512); (ii) 
TSE-T2WI (TE=92 ms; TR=3620 ms; flip angle α=120°; 
slice thickness, 2 mm; FOV=80 mm; resolution=256×256); 
(iii) FSIP-DWI (TE=6.22 ms; TR=15.3 ms; flip angle α=30°; 
slice thickness, 1 mm; FOV=80 mm; voxel=0.4 mm×0.4 
mm×1.0 mm; diffusion moment=0 and 50 mT m−1 ms−1; 
resolution=192×192). MRI scanning was performed 12 h 
after the pMCAO surgery and prior to sacrifice. 
1.5  Neurological deficit evaluation  
A thorough neurologic examination was performed on all 
animals after surgery. The neurologic findings were scored 
along a five-point scale based on the Zea-Longa scale [7] 
whereby zero indicated no neurologic deficit, a score of one 
(characterized by the failure to extend left forepaw fully) 
indicated a mild focal neurologic deficit, a score of two 
(characterized by circling to the left) indicated a moderate 
focal neurologic deficit and a score of three (characterized 
by falling to the left) indicated a severe focal deficit. Rats 
with a score of four did not walk spontaneously and had a 
depressed level of consciousness. 
1.6  TTC staining and infarct volume determination  
Twelve hours after performing the pMCAO surgery the 
animals were sacrificed. The brains were removed and se-
ries of 2 mm of coronal brain slices were collected (Brain 
Matrix, EHSY, Shanghai, China) and stained for 30 min at 
37°C in 0.2% TTC (2,3,5-triphenyl-tetrazolium chloride, 
Sigma, Missouri, USA) diluted in 0.1 mol L−1 phosphate 
buffer [10]. The infarct volume was measured by recording 
stained sections with a digital camera (Canon IXUS800, 
Canon, Tokyo, Japan) and the image of each section was 
analyzed by an image analyzer (Image Pro Plus 6.0, Media 
Cybernetics, Inc., Georgia, USA). The infarct area, which 
was not stained, was determined by counting pixels within 
the outlined regions of interest. Infarct volume was ex-
pressed as the ratio of pixels counted from the corrected 
infarct area to the pixels collected from the whole contralat-
eral hemisphere. We then compared the infarct regions with 
those derived from MRI. 
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1.7  Statistical analysis 
Values are presented as mean±SD. Statistical analysis was 
performed using SPSS 13.0. One-way analysis of variance 
followed by individual comparisons of means (LSD test, or 
Dunnet’s method when the data were not normally distrib-
uted) was used for the comparison of grouped data. Data 
showing P<0.05 were considered statistically significant. 
2  Results 
2.1  Intracranial administration of citicoline reduces 
infarct volume and neurological deficit of brain ischemic 
injury  
The results showed that IC administration of citicoline prior 
to pMCAO had a neuroprotective effect. These effects were 
confirmed at both the pathological (via TTC staining) and 
functional levels (via a Zea-Longa five-point scale). The 
best effect was observed in IC group 2 relative to all other 
groups (P<0.01, Table 1 and Figures 1 and 2). There was no 
statistical difference between IC groups 1, 3, 4 and 5, the IP 
group and the control group (P>0.05, Table 1 and Figures 1 
and 2). On the other hand, there was a statistical difference 
between IC group 2 and the IP group (P<0.01, Table 1 and 
Figures 1 and 2). As observed in a previous study, behav-
ioral deficits were correlated to the severity of the damage 
in the cortex [9]. Therefore, the improved neural function 
might be attributed to a rescue of the penumbra in external 
cortex by citicoline administration, which was confirmed by 
the MRI findings (Figure 2). 
2.2  MRI results at 12 h after pMCAO 
We also used MRI to monitor the pathological progression 
of all groups during ischemia. Generally, T1WI is good for 
anatomical imagine whereas T2WI is known to be highly 
sensitive to water content changes. The typical MRI 
changes associated with infarction, including decreased 
signal intensity on T1WI and increased signal intensity on 
T2WI [11], are presented to define the lesions for both lo-
calization and injury severity (Figure 2). 
The TTC staining and MRI showed different localiza-
tions of ischemic lesions in six of the groups. The typical 
changes of decreased signal intensity on T1WI and in-
creased signal intensity on T2WI, were well displayed in the 
infarct areas. Each group consisted of n=8 animals. 
3  Discussion 
In the present work, we have developed a simple diffusion 
delivery (SDD) technique, which has the potential to dis-
tribute the pharmacological agents more efficiently and less 
invasively within the brain parenchyma. Using this tech-
nique, a significant neuroprotective effect against cerebral 
ischemia can be achieved with a single injection of only a 
very small dose of the agent. The efficiency of SDD is 
based on the original injection point and the neuroprotective 
agents used. 
The design of the SDD system was based on brain inter-
stitial MRI tracer imaging using the gadolinium derivative 
Gd-DTPA whereby MRI can be used to trace the diffusion 
and distribution of Gd-DTPA within the brain interstitial 
space. Our previous study found that using the caudate nu-
cleus as the original injection point a single administration 
Gd-DTPA was able to diffuse to the MCA territory and 
where it remained almost unchanged for 2–4 h after the in-
jection [5]. In the current work, we assumed that a neuro-
protective agent similar to Gd-DTPA would diffuse in the 
same way as Gd-DTPA. Among the many candidates, citi-
coline was chosen because it is similar to Gd-DTPA in re-
spect to both molecular weight (510.31 Da vs. 938.02 Da) 
and polarity (both are hydrophilic). Additionally, because 
citicoline is an intermediate in the generation of phosphati-
dylcholine from choline in the normal brain, it is likely to be 
safer and more appropriate than other exogenous com-
pounds for this local intracranial drug delivery study [12].  
Citicoline is considered to be one of the most promising 
candidates for the treatment of acute ischemic stroke [13–16]. 
Its functions include accelerating resynthesis of phospholip-
ids and suppressing the release of free fatty acids, stabilizing 
cell membranes and reducing free radical generation [17]. 
However, the extremely low brain uptake of citicoline is 
one of the major obstacles affecting its efficacy as demon-
strated in meta-analysis of clinical trials assessing the 
concentration-dependent neuroprotective effects of citi-
coline [18]. More importantly, the limited volume fraction 
of brain microvessels (3% of the total brain volume) [19], 
and the post-ischemic hypoperfusion state before successful 
vascular recanalization therapy also make the infusion of 
citicoline to the infarct area even more difficult. In the pre-
sent work, using SDD after a single administration of small 
dose of citicoline resulted in significant protective effects. 
Our results indicate that citicoline successfully circum-
vented the BBB and suggests that the issue of poor delivery  




IC group 1 
(0.00125 g kg−1 citicoline) IC group 2 IC group 3 IC group 4 IC group 5 IP group 
Neurological score 2.9±0.8 2.9±0.8 1.6±0.9 1.9±0.4 2.0±1.2 1.7±0.6 2.0±0.8 
Infarct volume ratio (%) 27.7±10.5 27.5±11.9 4.1±2.0 24.0±12.9 23.5±11.7 30.3±18.8 24.0±10.4 
a) Animals from IC group 6 did not survive 12 h and were not included. For each group n=8 rats. 
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Figure 1  TTC staining and MRI results. Each group, except group 7, received an IC microinjection containing 5 μL saline (group 1, control group), 
0.00125 g kg−1 citicoline (group 2, IC group 1), 0.0025 g kg−1 citicoline (group 3, IC group 2), 0.00375 g kg−1 citicoline (group 4, IC group 3), 0.005 g kg−1 
citicoline (group 5, IC group 4), and 0.0125 g kg−1 citicoline (group 6, IC group 5). Animals from group 7 (IP group) received an IP injection of 2 g kg−1 citi- 
coline. For each group, two hours following injection, the rats received a permanent middle cerebral artery occlusion (pMCAO). 
 
Figure 2  The infarct volume ratio in the seven groups. Each group, except 
group 7, received an IC microinjection containing 5 μL saline (group 1, con-
trol group), 0.00125 g kg−1 citicoline (group 2, IC group 1), 0.0025 g kg−1 
citicoline (group 3, IC group 2), 0.00375 g kg−1 citicoline (group 4, IC 
group 3), 0.005 g kg−1 citicoline (group 5, IC group 4), and 0.0125 g kg−1 
citicoline (group 6, IC group 5). Animals from group 7 (IP group) received 
an IP injection of 2 g kg−1 citicoline. For each group, two hours following 
injection, the rats received a permanent middle cerebral artery occlusion  
(pMCAO). Each group consisted of n=8 animals. 
due to hypoperfusion may have also been overcome. 
In summary, we have developed a novel delivery tech-
nique for the treatment of CNS diseases. Compared with tra-
ditional techniques such as convection-enhanced delivery, 
SDD is more efficient and less invasive. Although the MRI 
tracer imaging enables a precise predictive control over the 
SDD process in our study, a reliable quantitative measure-
ment on the diffusion and clearance properties within brain 
interstitial space is the key to understanding the mechanism 
of SDD and enhancing its application for the treatment of 
CNS diseases. 
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